| Literature DB >> 31345014 |
Frederik Taylor Pitter1, Matt Sikora2, Martin Lindberg-Larsen3, Alma Becic Pedersen4, Benny Dahl5, Martin Gehrchen1.
Abstract
OBJECTIVE: To report the 1-year pre and postoperative analgesic use in patients undergoing primary surgery for adult spinal deformity (ASD) and assess risk factors for chronic postoperative opioid use.Entities:
Keywords: Adult spinal deformity surgery; Analgesics; Chronic opioid use; Opioids; Pain
Year: 2019 PMID: 31345014 PMCID: PMC7136115 DOI: 10.14245/ns.1938106.053
Source DB: PubMed Journal: Neurospine ISSN: 2586-6591
Fig. 1.Patient selection. ASD, adult spinal deformity. *Not all sub diagnosis included.
Demographic data for the 892 patients undergoing first time adult spinal deformity surgery, overall and divided into preoperative chronic opioid user and nonuser
| Variable | All patients | Preoperative | p-value | |
|---|---|---|---|---|
| Chronic opioid user | Chronic opioid nonuser | |||
| Sex | 0.011 | |||
| Male | 34.0 (303) | 27.2 (67) | 36.5 (236) | |
| Female | 66.0 (589) | 72.8 (179) | 63.5 (410) | |
| Age at surgery (yr) | ||||
| Median (IQR) | 51.0 (27.0–65.0) | 61.0 (51.2–69.0) | 44.0 (22.0–62.0) | < 0.001 |
| Mean ± SD | 47.9 ± 19.6 | 58.9 ± 13.6 | 43.7 ± 20.0 | < 0.001 |
| Charlson comorbidity index score | < 0.001 | |||
| Low (0) | 560 (62.8) | 120 (48.8) | 440 (68.1) | |
| Medium (1–2) | 268 (30.0) | 97 (39.4) | 171 (26.5) | |
| High (3–9) | 64 (7.2) | 29 (11.8) | 35 (5.4) | |
| Preoperative chronic antidepressant user | < 0.001 | |||
| No use | 90.0 (803) | 78.9 (194) | 94.3 (609) | |
| Use | 10.0 (89) | 21.1 (52) | 5.7 (37) | |
| Preoperative chronic anticonvulsants user | < 0.001 | |||
| No use | 90.0 (803) | 82.5 (203) | 92.9 (600) | |
| Use | 10.0 (89) | 17.5 (43) | 7.1 (46) | |
Values are presented as number (%) unless otherwise indicated.
IQR, interquartile range; SD, standard deviation.
Number of users of given drug/drug group in each quarter
| Analgesic | Drug | -Q4 | -Q3 | -Q2 | -Q1 | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|---|---|---|---|---|
| NSAID | |||||||||
| Paracetamol | |||||||||
| Opioids | |||||||||
| Ketogan | 14 | 14 | 11 | 14 | 21 | 8 | 10 | 7 | |
| Tramadol | 158 | 167 | 177 | 174 | 242 | 143 | 132 | 133 | |
| Contalgin/morphine | 41 | 51 | 59 | 65 | 352 | 115 | 99 | 92 | |
| Codeine/kodamid | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | |
| Hydromorphine | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 1 | |
| Oxycodone | 45 | 45 | 48 | 53 | 317 | 106 | 91 | 79 | |
| Fentanyl | 9 | 12 | 15 | 15 | 27 | 16 | 18 | 17 | |
| Buprenorphine | 10 | 15 | 15 | 19 | 19 | 11 | 7 | 8 | |
| Nicomorphine | 4 | 0 | 2 | 2 | 18 | 1 | 1 | 0 | |
| Tapentadol | 1 | 1 | 2 | 1 | 3 | 2 | 2 | 2 | |
| Petidine | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | |
| Methadone | 18 | 16 | 12 | 14 | 17 | 15 | 16 | 17 | |
| Antidepressants | |||||||||
| Amitriptyline | 19 | 20 | 13 | 14 | 26 | 25 | 33 | 25 | |
| Nortriptyline | 4 | 3 | 3 | 3 | 11 | 11 | 10 | 11 | |
| Imipramine | 3 | 3 | 2 | 2 | 2 | 3 | 1 | 1 | |
| Duloxetine (SNRI) | 2 | 1 | 1 | 1 | 0 | 2 | 1 | 2 | |
| Venlafaxine (SNRI) | 14 | 16 | 16 | 15 | 13 | 16 | 15 | 13 | |
| Citalopram/escitalopram (SSRI) | 42 | 42 | 34 | 35 | 35 | 37 | 41 | 45 | |
| Sertraline | 14 | 16 | 13 | 14 | 12 | 14 | 12 | 12 | |
| Anticonvulsants | |||||||||
| Gabapentin | 30 | 38 | 36 | 46 | 76 | 62 | 65 | 51 | |
| Pregabalin | 21 | 21 | 19 | 20 | 20 | 22 | 25 | 27 | |
| Topiramat | 10 | 11 | 9 | 10 | 8 | 8 | 8 | 7 | |
| Lamotrigine | 15 | 16 | 16 | 16 | 15 | 16 | 17 | 19 | |
| Carbamazpin | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 5 | |
| Oxcarbazepin | 8 | 7 | 6 | 7 | 5 | 7 | 7 | 7 | |
| Valproate | 13 | 10 | 11 | 13 | 15 | 16 | 16 | 14 | |
| Other | Glucosamine | 20 | 17 | 22 | 12 | 7 | 8 | 7 | 4 |
| Indometacin | 1 | 1 | 0 | 0 | 1 | 2 | 1 | 1 | |
| Magnyl | 5 | 5 | 3 | 4 | 3 | 4 | 3 | 3 | |
| Codeine (cough) | 30 | 33 | 37 | 39 | 42 | 28 | 31 | 23 |
NSAID, nonsteroidal anti-inflammatory drugs; Q, quarter; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
Fig. 2.Number of users of each drug group per quarter. NSAID, nonsteroidal anti-inflammatory drug.
Development of analgesic use after primary adult spinal deformity surgery for the 796 patients without revision or death within 1-year of follow-up
| Analgesic | Preoperative use (n) | Development | Q1 vs. Preop | Q2 vs. Q1 | Q3 vs. Q2 | Q4 vs. Q3 |
|---|---|---|---|---|---|---|
| NSAID | Chronic user (140) | Sustained | 46 | 32 | 30 | 26 |
| Discontinued | 94 | 14 | 2 | 4 | ||
| Chronic nonuser (656) | New, sustained | 72 | 14 | 9 | 6 | |
| Discontinued | - | 58 | 5 | 3 | ||
| Paracetamol | Chronic user (145) | Sustained | 126 | 113 | 100 | 84 |
| Discontinued | 19 | 13 | 13 | 16 | ||
| Chronic nonuser (651) | New, sustained | 189 | 93 | 68 | 58 | |
| Discontinued | - | 96 | 25 | 10 | ||
| Opioids | Chronic user (208) | Sustained | 202 | 163 | 146 | 133 |
| Discontinued | 6 | 39 | 17 | 13 | ||
| Chronic nonuser (588) | New, sustained | 472 | 113 | 79 | 59 | |
| Discontinued | - | 359 | 34 | 20 | ||
| Antidepressants | Chronic user (79) | Sustained | 62 | 53 | 46 | 43 |
| Discontinued | 17 | 9 | 7 | 3 | ||
| Chronic nonuser (717) | New, sustained | 41 | 19 | 18 | 16 | |
| Discontinued | - | 22 | 1 | 2 | ||
| Anticonvulsants | Chronic user (76) | Sustained | 61 | 55 | 51 | 49 |
| Discontinued | 15 | 6 | 4 | 2 | ||
| Chronic nonuser (720) | New, sustained | 48 | 27 | 25 | 19 | |
| Discontinued | - | 21 | 2 | 6 |
Preop, preoperative; NSAID, nonsteroidal anti-inflammatory drugs; Q, quarter.
Fig. 3.Number of patients with continued postoperative opioid use. Divided by preoperative chronic user and nonuser. Preop., preoperative.
Multiple logistic regression on risk factors for chronic postoperative opioid use in 796 patients
| Unadjusted odds ratios | Adjusted odds ratios | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p-value | OR | 95% CI | p-value | |
| Sex | ||||||
| Male | 0.65 | 0.45–0.93 | 0.018 | 0.75 | 0.48–1.16 | 0.192 |
| Female | Reference | - | - | Reference | - | - |
| Age, per 10 years | 1.53 | 1.39–1.69 | < 0.001 | 1.30 | 1.15–1.46 | < 0.001 |
| Charlson Comorbidity Index (CCI) score[ | ||||||
| Low | Reference | - | - | Reference | - | - |
| Medium | 1.82 | 1.28–2.59 | < 0.001 | 1.18 | 0.76–1.83 | 0.462 |
| High | 1.71 | 0.92–3.19 | 0.093 | 0.58 | 0.26–1.27 | 0.172 |
| Preoperative chronic anticonvulsant use | ||||||
| User | 2.71 | 1.66–4.40 | < 0.001 | 1.67 | 0.88–3.18 | 0.118 |
| Nonuser | Reference | - | - | Reference | - | - |
| Preoperative chronic antidepressant use | ||||||
| Use | 2.84 | 1.76–4.58 | < 0.001 | 0.97 | 0.52–1.81 | 0.918 |
| Nonuser | Reference | - | - | Reference | - | - |
| Preoperative chronic opioid use | ||||||
| Use | 15.90 | 10.76–23.49 | < 0.001 | 11.76 | 7.77–17.79 | < 0.001 |
| Nonuser | Reference | - | - | Reference | - | - |
OR, odds ratio; 95% CI, 95% confidence interval.
Comorbidity burden is summarized into low (CCI score = 0), medium (CCI score = 1–2), and high (CCI score = 3–9).